Tonix Pharmaceuticals Announces Presentation of Data Supporting Development of Racemic and Single (S)-Isomer Tianeptine, Plastogen Anti-Depressants, at the American Society of Clinical Psychopharmacology Meeting
June 05, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Tianeptine’s Mechanism of Restoring Neuroplasticity and Neurogenesis by Dual PPAR-β/δ and PPAR-γ Agonism Supports Development as a First-in-Class Oral Therapy for Psychiatric and Neurodegenerative...
Tonix Pharmaceuticals Announces Presentations Involving TNX-1500 (anti-CD40L mAb) at the 2023 American Transplant Congress
May 31, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an upcoming...
Tonix Pharmaceuticals Announces Presentation at the 2023 BIO International Convention
May 30, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth...
Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 25, 2023 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has...
Tonix Pharmaceuticals Announces Poster Presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 25, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Gregory Sullivan, M.D., Chief...
Tonix Pharmaceuticals to Present at the June 1st Virtual Investor Summit
May 24, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating...
Tonix Pharmaceuticals Announces the Isolation and Characterization of the (S)-Isomer of Tianeptine, TNX-4300 (Estianeptine), Now Under Development for Psychiatric and Neurodegenerative Diseases
May 23, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-4300 is a Dual PPAR-β/δ and PPAR-γ Agonist, Free from µ-Opioid Receptor Activity TNX-4300’s Mechanism of Restoring Neuroplasticity Supports Development as a First-in-Class Oral Therapy for...
Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin)
May 22, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Intranasal Oxytocin Blocks the Release of CGRP in Animal Models Intranasal Oxytocin is the Core Technology of TNX-1900 for Migraine Oxytocin Treatment Affects a Pathway that is Distinct from the...
Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference
May 18, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., May 18, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that management will participate in...
Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression
May 17, 2023 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Research Supports Direct Role for Restoring Neuroplasticity and Upsets Previously Held Beliefs About the Significance of Neurotransmitters in Treating Depression Findings Explain Why Tianeptine Is...